Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of target-controlled infusion remifentanil for blunting intubation response in severe preeclampsia during cesarean section
ChiCTR1900022174Phase 4Recruiting
- Sponsor
- Jiaxing Maternity and Child Health Care Hospital
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remifentanil in preeclampsia (5 arms), sponsored by Jiaxing Maternity and Child Health Care Hospital. Primary endpoints: Blood pressure, Apgar score and 1 more. Started Apr 2019; status: recruiting.
02
Drugs
remifentanil
03
Conditions
preeclampsia
Beyond the preview
Go deeper on ChiCTR1900022174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022174.